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ABSTRACT
Objectives To assess quality of reporting of sample size
calculation, ascertain accuracy of calculations, and
determine the relevance of assumptions made when
calculating sample size in randomised controlled trials.
Design Review.
Data sourcesWesearchedMEDLINEforallprimaryreports
of two arm parallel group randomised controlled trials of
superiority with a single primary outcome published in six
high impact factor general medical journals between 1
January 2005 and 31 December 2006. All extra material
related to design of trials (other articles, online material,
onlinetrialregistration)wassystematicallyassessed.Data
extracted by use of a standardised form included
parameters required for sample size calculation and
correspondingdatareportedinresultssectionsofarticles.
We checked completeness of reporting of the sample size
calculation, systematically replicated the sample size
calculation to assess its accuracy, then quantified
discrepancies between a priori hypothesised parameters
necessary for calculation and a posteriori estimates.
Results Of the 215 selected articles, 10 (5%) did not
report any sample size calculation and 92 (43%) did not
report all the required parameters. The difference
between the sample size reported in the article and the
replicated sample size calculation was greater than 10%
in 47 (30%) of the 157 reports that gave enough data to
recalculate the sample size. The difference between the
assumptions for the control group and the observed data
was greater than 30% in 31% (n=45) of articles and
greater than 50% in 17% (n=24). Only 73 trials (34%)
reported all data required to calculate the sample size,
had an accurate calculation, and used accurate
assumptions for the control group.
Conclusions Sample size calculation is still inadequately
reported, often erroneous, and based on assumptions
that are frequently inaccurate. Such a situation raises
questions about how sample size is calculated in
randomised controlled trials.
INTRODUCTION
Theimportanceofsamplesizedeterminationinrando-
mised controlled trials has been widely asserted, and
according to the CONSORT statement these
calculations must be reported and justified in pub-
lishedarticles.
1-4Theaimof ana priorisamplesize cal-
culation is mainly to determinate the number of
participantsneededtodetectaclinicallyrelevanttreat-
menteffect.
56Some haveassertedthat oversizedtrials,
which expose too many people to the new therapy, or
underpowered trials, which may fail to achieve signifi-
cant results, should be avoided.
7-12
Theusualconventionalapproachistocalculatesam-
ple size with four parameters: type I error, power,
assumptions in the control group (response rate and
standard deviation), and expected treatment effect.
5
Type I error and power are usually fixed at conven-
tional levels (5% for type I error, 80% or 90% for
power). Assumptions related to the control group are
oftenpre-specifiedon the basis ofpreviously observed
data or published results, and the expected treatment
effect is expected to be hypothesised as a clinically
meaningful effect. The uncertainty related to the rate
of events or the standard deviation in the control
group
1314 and to treatment effect could lead to lower
than intended power.
6
We aimed to assess the quality of reporting sample
size calculation in published reports of randomised
controlled trials, the accuracy of the calculations, and
the accuracy of the a priori assumptions.
MATERIALS AND METHODS
Search strategy
We searched MEDLINE via PubMed with the search
terms“randomizedcontrolledtrials”and“randomised
controlled trials” for articles published in six general
journals with high impact factors: New England Journal
of Medicine, Journal of the American Medical Association
(JAMA), The Lancet, Annals of Internal Medicine, BMJ,
and PLoS Medicine between 1 January 2005 and 31
December 2006. One of us (PC) screened titles and
abstracts of retrieved articles to identify relevant arti-
cles,withthehelpofasecondreviewer(AD)ifneeded.
Selection of relevant articles
We included all two arm, parallel group superiority
randomisedcontrolledtrialswithasingleprimaryout-
come.Weexcludedreportsforwhichthe studydesign
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report that presented the results for the primary out-
come. We excluded follow-up studies.
Data abstraction
For all selected articles, we systematically retrieved
and assessed the full published report of the trial, any
extra material or appendices available online, the
study design article, if cited, and the details of online
registration of the trial, if mentioned. A standardised
data collection form was generated on the basis of a
review of the literature and a priori discussion and
testedbytheresearchteam.Werecordedthefollowing
data.
In the full text of the articles
General characteristics of the studies: including the
medical area, whether the trial was multicentre, the
type of treatment (pharmacological, non-pharmacolo-
gical, or both), the type of primary endpoint (dichoto-
mous, time to event, continuous), and the funding
source (public, private, or both).
Details of the a priori sample size calculation as
reported in the materials and methods section: we
notedwhetherthesamplesizecalculationwasreported
and, if so, the target sample size. We also collected all
the parameters used for the calculation: type I error,
one or two tailed test, type II error or power, type of
test,assumptionsinthecontrolgroup(rateofeventsfor
dichotomousandtimetoeventoutcomesandstandard
deviation for continuous outcomes), and the predicted
treatment effect (rate of events in the treatment group
for dichotomous and time to event outcomes, mean
difference or effect size [defined in appendix 1] for
continuous outcomes). Any justification for assump-
tions made was also recorded.
Observed data as reported in the results section:
number of patients randomised and analysed was
recorded, and results for the control group. We also
noted whether the results of the trial were statistically
significant for the primary outcome.
In the online extra material or study design article
Werecordedthetargetsamplesizeandalltherequired
parametersforsamplesizecalculationifdifferentfrom
those reported in the article.
In the trial registration website
We noted the target sample size and all the required
parameters for sample size calculation.
One of us (PC) independently completed all data
extractions. A second member of the team (AD)
reviewed a random sample of 30 articles for quality
assurance. The κ statistic provided a measure of inter-
observer agreement. The reviewers were not blinded
to the journal name and authors.
Data analysis
Replication of sample size calculation
We replicatedthe samplesize calculationfor each arti-
clethatprovidedallthedataneededforthecalculation.
Ifparametersforreplicatingthesamplesizeweremiss-
ing in the article and if the calculation was described
elsewhere (in the online extra material or study design
article) we used the parameters given in this supple-
mental material. If the missing values were only the α
risk or whether the test was one or two tailed, we
hypothesised an α risk of 0.05 with a two tailed test to
replicatethecalculation.Samplesizecalculationswere
replicated by one of us (PC) with nQuery Advisor ver-
sion4.0(StatisticalSolutions,Cork,Ireland).Forabin-
ary endpoint, the replication used the formulae
adapted for a χ
2 test or Fisher’s exact test if specified
in the available data. For a time to event endpoint the
replication used the formulae adapted for a log rank
test, and for a continuous endpoint the replication
usedthe formulaeadaptedfor Student’st test.Thefor-
mulae used for the replication are provided and
explained in appendix 1. If the absolute value of the
standardised difference between the recalculated sam-
ple size and the reported sample size was greater than
10%, an independent statistician (GB) extracted the
data from the full text independently and replicated
the sample size calculation again. Any difference
between the two calculations was resolved by consen-
sus. The standardised difference between the reported
sample size calculation and the replicated one is
defined by the reported sample size calculation minus
the recalculated sample size divided by the reported
sample size calculation.
Comparisons between a priori assumptions and observed
data
To assess the accuracy of a priori assumptions, we cal-
culated relative differences between hypothesised
References (n=1070)
Articles selected (n=374)
Articles excluded on basis of title and abstract (n=696):
  No trials (e.g. letters, review) (n=494)
  Randomised trials (n=202):
    More than two arms (n=112)
    Cluster (n=39)
    Equivalence (n=18)
    Cost-efficacy (n=17)
    Cross-over (n=9)
    Factorial design (n=7)
Articles excluded on basis of full text (n=159):
  Follow-up studies (n=29)
  More than one trial (n=1)
  Not randomised (n=1)
  Exclusion because of design:
    Equivalence or non-inferiority (n=35)
    Factorial design (n=11)
    More than 2 arms (n=10)
    Cluster (n=3)
    Cost-efficacy (n=2)
    Two randomisations (n=1)
  Exclusion because of primary outcome:
    More than one primary outcome (n=62)
    No primary outcome (n=4) 
Articles for analysis (n=215)
Fig 1 | Study screening process
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rials and methods sections of articles and estimated
ones reported in the results sections. We calculated
relative differences for standard deviations if the out-
come was continuous (standard deviation in the mate-
rials and methods section minus standard deviation in
the resultssectiondividedby standarddeviation inthe
materials and methods section) or for event rates for a
dichotomous or time to event outcome (event rates in
thematerialsandmethodssectionminuseventratesin
the results section divided by event rates in the materi-
alsandmethodssection).Therelationbetweenthesize
ofthe trialand the differencebetweenthe assumptions
and observed data was explored by use of Spearman’s
correlationcoefficient,andits95%confidenceinterval
was estimated by bootstrap.
Statistical analyses were done with SAS version 9.1
(SASInstitute,Cary,NC),andRversion4.1(FreeSoft-
ware Foundation’s GNU General Public License).
RESULTS
Selected articles
Figure 1 summarises selection of articles. The electro-
nicsearchyielded1070citations,including281reports
of parallel group superiority randomised controlled
trials with two arms. We selected 215 articles (appen-
dix 2) that reported only one primary outcome.
Description of trials
Table 1 describes the characteristics of the included
studies. The median sample size of the trials was 425
(interquartile range [IQR] 158-1041), and 112 reports
(52.1%)claimedsignificantresultsfortheprimaryend-
point.Seventy-sixpercentweremulticentretrials,with
a median of 23 centres (IQR 7-59). The three most fre-
quent medical areas of investigation were cardio-
vascular diseases (26%; n=56 articles), infectious
diseases (11%; n=24), and haematology and oncology
(10%; n=22). Interobserver agreement in extracting
the data from reports was good; κ coefficients ranged
from 0.76 to 1.00.
Reporting of required parameters for a priori sample size
calculation
Ten articles (5%) did not report any sample size calcu-
lation. Only 113 (53%) reported all the required para-
meters for the calculation. Table 2 describes the
reporting of necessary parameters for sample size
calculation.
The median of the expected treatment effect for
dichotomous or time to event outcomes (relative dif-
ference of event rates) was 33.3% (IQR 24.8-50.0) and
the median of the expected effect size for continuous
outcomes was 0.53 (0.40-0.69) (fig 2).
The design of 35 of the 215 trials (16%) was
described elsewhere. In two, the primary outcome
described in the report differed from that in the design
article. In 31 articles (89%), the data for sample size
calculationweregiven.For16articles(52%)thereport-
ing of the assumptionsdiffered from the design article.
Table 1 |Characteristics of 215 included studies
Characteristic N (%)
Journal of publication
New Engl J Med 80 (37)
Lancet 46 (21)
JAMA 39 (18)
BMJ 36 (17)
Ann Intern Med 12 (6)
PLoS Med 2( 1 )
Year of publication
2005 109 (51)
2006 106 (49)
Median number of randomised patients (IQR) 425 (158-1041)
Multicentre trial 163 (76)
Intervention
Pharmacological 131 (61)
Nonpharmacological 74 (34)
Both 10 (5)
Outcome
Dichotomous 100 (47)
Time to event 67 (31)
Continuous 48 (22)
Funding
Only public 126 (59)
Only private 49 (23)
Both public and private 38 (18)
Unclear 2 (1)
IQR=interquartile range.
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Fig 2 | Histogram of assumptions of treatment effect. For
dichotomous and time to event outcomes: relative difference
of event rates (larger rate minus smaller rate, divided by rate
in control group). For continuous outcomes: standardised
effect size.
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registration database
Of the 215 selected articles, 113 (53%) reported regis-
tration of the trial in an online database. Among them,
87 (77%) were registered in ClinicalTrials.gov, 23
(20%) in controlled-trials.com (ISRCTN registry),
and three (3%) in another database. For 96 articles
(85%), an expected sample size was givenin the online
database and was equal to the target sample size
reported in the article in 46 of these articles (48%).
The relative difference between the registered and
reported sample size was greater than 10% in 18 arti-
cles (19%) and greater than 20% in five articles (5%).
The parameters for the sample size calculation were
not stated in the online registration databases for any
of the trials.
Replication of sample size calculation
We were able to replicate sample size calculations for
164 articles: 113 reported all the required parameters,
and 51 that omitted only the α risk or whether the test
was one or two tailed. We were able to compare our
recalculated sample size and the target sample size for
157 articles, since seven did not report any target sam-
ple size.Thesample sizerecalculationwasequal tothe
authors’ target sample size for 27 articles (17%) and
close (absolute value of the difference <5%) for 76
(48%). The absolute value of the difference between
the replicated sample size calculation and the authors’
target sample size was greater than 10% for 47 articles
(30%) and greater than 50% for 10 (6%). Twenty-eight
recalculations (18%) were 10% lower than reported
sample size, and 19 recalculations (12%) were larger
thanreportedsamplesize(fig3).Theresultsweresimi-
larwhenweanalysedonlythe113articlesreportingall
the required parameters.
Comparisons between a priori parameters and
corresponding estimates in results section
A comparison between the a priori assumptions and
observed data was feasible for 145 of the 157 articles
reportingenoughparameterstorecalculatethesample
size and reporting the results of the authors’ calcula-
tions.
Assumptions about control group
The median relative difference between the control
group pre-specified parameters and their estimates
was 3.3% (IQR −16.7 to 21.4). The median difference
was 2.0% (−15 to 21) for dichotomous or time to event
outcomes and 11% (−24 to 27) for continuous out-
comes. The absolute value of the relative difference
was greater than 30% for 45 articles (31%) and greater
than 50% for 24 (17%). Figure 4 shows that the differ-
ences between the assumptions and the results were
large and small in roughly even proportions, whether
the results were significant or not. The size of the trial
and the differences between the assumptions for the
control group and the results did not seem to be sub-
stantially related (rho=0.03, 95% confidence interval
−0.05 to 0.15).
Overall, 73 articles (34%) reported enough para-
meters for us to replicate the sample size calculation,
had an accurate calculation (the replicated sample size
calculationdifferedbylessthan10%fromthereported
target sample size), and had accurate assumptions for
the control group (the differences between the a priori
assumptions and their estimates was less than 30%)
(fig 5).
Table 2 |Reporting of parameters required for a priori sample size calculation for the 215
articles
Parameter Reporting frequency (%)
α risk 191 (93)
0.05 183 (96)
Two tailed test 119 (65)
One tailed test 7 (4)
Unspecified 57 (31)
0.025 for one tailed test 2 (1)
Adapted for interim analyses 6 (3)
Power 200 (98)
80% 107 (54)
85% 9 (5)
90% 66 (33)
95% 4 (2)
Other values 14 (7)
Assumptions for control group 165 (81)
Justification of assumptions 81 (49)
Results from previous trial 54 (67)
Preliminary study 15 (19)
Observational data 6 (7)
Results of systematic review 2 (3)
Others 4 (5)
Assumptions for the treatment effect 186 (91)
Justification of the assumptions 50 (27)
Analogy to another trial or treatment 41 (82)
Clinical relevance 7 (14)
Observational data 1 (2)
Results of a meta-analysis 1 (2)
All parameters required for sample size calculation 113 (53)
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Fig 3 | Differences between target sample size and replicated
sample size calculations. Differences in sample size
calculations are relative differences between target sample
size given in materials and methods section of articles and
our recalculation with the parameters provided. Box
represents median observations (horizontal rule) with 25th
and 75th percentiles of observed data (top and bottom of
box). Length of each whisker is 1.5 times interquartile range.
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Principal findings
Inthissurveyof215reportspublishedin2005and2006
insixgeneralmedicaljournalswithhighimpactfactors,
only about a third (n=73, 34%) adequately described
sample size calculations—ie, they reported enough
data to recalculate the sample size, the sample size cal-
culation was accurate, and assumptions in the control
group differed less than 30% from observed data. Our
study raises two main issues. The first is the inadequate
reporting and the errors in sample size calculations,
which are surprising in high quality journals with a
peer review process; the second is the large discrepan-
ciesbetweentheassumptionsandthedataintheresults,
which raises a much more complex problem because
investigators often have to calculate a sample size with
insufficient data to estimate these assumptions.
Reporting of the sample size calculation has greatly
increased in the past decades, from 4% of reports
describing a calculation in 1980 to 83% of reports in
2002.
1516 However, our review highlights that some
of the required parameters for sample size calculation
are frequently absent in reports and that sample size
miscalculations unfortunately occur in randomised
controlled trials. We were not able to identify the rea-
sons for such erroneous calculations, particularly the
frequency of reported calculations that were greater
than our recalculation. Surprisingly, such errors
(sometimes large) were missed during the review
process.
We also found large discrepancies between values
for assumed parameters in the control group used for
sample size calculations (ie, event rate or standard
deviation in the control group) and estimated ones
from observed data. Assumed values were fixed at a
higher or lower level than corresponding data in the
results sections in roughly even proportions, a finding
different from the results of a previous study: Vickers
showedthatthesamplestandarddeviationwasgreater
than the pre-specified standard deviation for 80% of
endpoints in randomised trials.
14
Although the CONSORT group recommends
reporting details of sample size determination to iden-
tify the primary outcome and as a sign of proper trial
planning, our results suggest that researchers,
reviewers, and editors do not take reporting of sample
size determination seriously.
17 In this case, an effort
should be made to increase transparency in sample
size calculation or, if sample size calculation reporting
is of little relevance in randomised controlled trials,
perhapsitshouldbeabandoned,ashasbeensuggested
by Bacchetti.
18
Limitations
An important limitation of this study is that we could
not directly assess whether assumptions had been
manipulated to obtain feasible sample sizes because
we used only published data. Assumptions can be
first adapted when planning the trial, by retrofitting
the assumption estimates to the available participants,
also called “sample size samba” by Schulz and
Grimes.
6 This situation is impossible to assess without
attending the discussionbetween the investigators and
statisticians. The sample size calculation can also be
manipulated after the completion of the study, as
Chan and coworkers have recently shown by compar-
ing protocols to final articles.
19
Weincludedonlytwoarmparallelgroupsuperiority
randomisedcontrolledtrialswithasingleprimaryout-
come, so we did not assess more complex sample size
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Fig 4 | Relative differences between assumptions and results
for control groups
Articles not reporting a sample size calculation (n=10)
Selected articles (n=215)
Articles reporting sample size calculations (n=215)
Articles reporting necessary assumptions to replicate the sample size calculation (n=164)
Articles with accurate sample size calculations (n=73) defined as:
  Necessary assumptions reported
  AND difference between the replicated and the target sample size < 10%
  AND assumptions in the control group differing < 30% from observed data
Articles replicating sample size calculations
>10% different from target sample size (n=164)
Articles replicating sample size calculations
<10% different from target sample size (n=110)
Possible comparisons between
assumptions and observed data (n=45)
Possible comparisons between
assumptions and observed data (n=100)
Articles with
assumptions in control
group differing <30%
from observed data
(n=27)
Articles in which assumptions and
observed data could not be compared (n=2)
Articles in which assumptions and
observed data could not be compared (n=10)
Articles not reporting target sample size (n=7)
Articles missing assumptions in control group only (n=18)
Articles missing expected treatment effect and assumptions in control group (n=17)
Articles missing power and expected treatment effect and assumptions in control group (n=3) 
Articles missing power and expected treatment effect (n=1)
Articles missing correction rate for drop outs (n=2)
Articles with
assumptions in control
group differing >30%
from observed data
(n=18)
Articles with
assumptions in control
group differing <30%
from observed data
(n=73)
Articles with
assumptions in control
group differing >30%
from observed data
(n=27)
Fig 5 | Articles selected for analysis of sample size calculations
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neoussampleofarticles.Wealsoselectedonlygeneral
medicaljournalswithahighimpactfactor.Lowimpact
factorjournalscouldhavethesameorlowermethodo-
logical quality. We chose one hypothesis when we
recalculated the sample size: the α risk was set at 0.05
for a two tailed test when one (or two) of these para-
meters was missing. Nevertheless, the proportion of
inadequate calculations did not change whether we
excluded these articles or not.
Implications
A major discrepancy exists between the importance
given to sample size calculation by funding agencies,
ethics review boards, journals, and investigators and
the current practice of sample size calculation and
reporting.
20 Sample size calculations are frequently
based on inaccurate assumptions for the control
group, calculations are often erroneous, and the
hypothesised treatment effect is often fixed a
posteriori.
6 This statement does not even take into
account that the primary outcome reported in the
initial protocol (on which the sample size calculation
was theoretically based) was found to differ from the
primary outcome of the final report in 62% of trials.
21
As written by Senn, “the sample size calculation is an
excuseforasamplesize,notareason,”andthecurrent
calculation of sample size is actually mainly driven by
feasibility.
920
We wonder whether the questions raised by our
results should join the debate on the ethics of under-
powered trials. Although underpowered trials are
viewed as unethical by many people, others consider
such trials ethical in that some evidence is better than
none
622andsuchtrialscouldevenproducemoreinfor-
mation than larger studies.
23 Furthermore, results of
underpowered trials contribute to the body of knowl-
edge and are useful for meta-analysis.
20 We therefore
believe, as do others, that there is room for reflection
on how sample size should be determined for rando-
mised trials.
2425 After years of trials with supposedly
inadequate sample sizes, it is time to develop and use
new ways of planning sample sizes.
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WHAT IS ALREADY KNOWN ON THIS SUBJECT
Planning and reporting of sample size calculation for randomised controlled trials is
recommended by ICH E9 and the CONSORT statement
WHAT THIS STUDY ADDS
Sample size calculations are inadequately reported, often erroneous, and based on
assumptions that are frequently inaccurate
These major issues question the foundation of sample size calculation and its reporting in
randomised controlled trials
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